Ceapro Inc V.CZO

NASDAQ Uplisting:

[prophetoffactz]

Uplisting to an international exchange such as NASDAQ is not only a goal for 2023, with only about six months left in the year, it was regarded as very important by Gilles at the AGM if the company is going to unlock value and advance as a biopharma. The company needs greater exposure. Acquiring other products on the market is also being looked at. The company has already actively investigated listed companies for a potential reverse-takeover in the US. Perhaps a NASDAQ uplisting could be timed with a CoQ10 PGX deal with a serious partner. CoQ10 is a $4 billion market Gilles notes and CZO appears to have a unique selling point given the bioavailability study. Yeast beta glucan is a $1 billion market. The 'go / no go' fibrosis clinical trial decision is also to be made this summer. Avalyn Pharma raised C$80 million going into its Phase I inhaled fibrosis drug trial and it used some of the same scientists at McMaster. Dr. Kolb believes CZO could profoundly alter the landscape for fibrosis should results seen in mice be replicated in humans. The avenanthramide clinical trial is also expected to begin enrollment this month with Phase I completed by the endo f the year. The comapny needs US$4 for NASDAQ and a buffer for safety. 

AGM: A little more in detail...

All nominations to the Board were approved. Glen Rourke didn't stand for re-election.

Ronnie Miller, "With our sound core business and multi-product pipeline these are indeed exciting times at your company...While we are always facing some challenges I do believe we are poised for growth which I'm convinced will bring Ceapro and all of its stakeholders excellent results as we move forward".

Gilles, "I echo Ronnie's comments regarding the fact that we have built a very solid company that is poised for growth". 

Very confident for another solid year for the base business once the re-ordering commences as previously mentioned. Working on a powdered formulation for beta glucan for the cosmetics industry. Looking at other peptides. Functional food: oat flour/avenanthramide opportunity for food and beverages. Commercial scale-up of the avenanthramide malting technology almost complete.

CZO has shown 2X CoQ10 bioavailability of cyclodextrine and 4X bioavailability of Triolien.  Discussions concerning out-licensing a PGX complex are underway right now with serious potential partners in the neutraceutical industry.  Partners are pretty impressed and understand why CZO wants to make bioavailability the unique selling point. Sigrun Watson is holding discussions with very, very serious partners. The goal is still a license by the end of the year. CoQ10 is a $4 billion market. 

CZO's new Senior VP of Technical Operations hired at the end of April has PGX scale-up as his first mandate. He has significant experience in multiple industries and has brought a different perspective that may both reduce costs and save time for PGX scale-up. No mention about how much time and costs could be saved. Plant construction is expected by the end of the year. Equipment is ready to be shipped from Europe. Completion of PGX scale-up is a critical success factor. The site design has been completed. The PGX equipment from Germany has been refurbished and is ready to be shipped.

CZO is confident that the Phase I portion of the avenanthramide clinical trial will be completed by the end of this year. Health Canada gave approval for the trial in December. The Montreal Heart Institute assumes responsibility for the trial and had to have all of its questions addressed by CZO. Questions have been addressed. Final approval from the Ethics Committe of the Montreal Heart Institute has been given. CZO is training the bioanalytics company that will be in charge of the blood samples how to measure the results given CZO's unique experience with avenanthramide. CZO will be testing 100X higher dosing than in the exercise inflammation study. Based on the human exercise inflammation study at the University of Minnisota CZO is confident in a very interesting outcome.

The 'go / no go' decision for the fibrosis drug is anticipated in the second half of the year. Animal trials are ongoing with a larger number of animals to provide additional comfort concerning the numbers and for regulators. CZO believes it has made a major discovery - PGX-YBG brings the macrophage back to its normal state. Hopes for Phase I trial pending ongoing studies.  

Cannabis is still in the pipeline but has been given a lower priority given what is happening in the industry at this time.

CZO has shown highly positive finding for beta glucan and avenanthramide for wound healing as in the release. Wounds look more normal. Dr. William Li will be presenting a virtual event for the wound healing opportunity and the next steps given the recent strong results. "Very, very successful study..." Will look at a franchinse in wound healing given results from McMaster and from the Angogenesis Foundation.

An uplisting to an international exchange is back in CZO's priorities. Reverse mergers have been investigated as one option. Given the historic bear market in biotech there may be an opportunity to reverse merge with another company as they struggle.

Avenanthramide scale-up using a malting technology is low hanging fruit as it is almost at commercial-scale as we speak. Could be used for the pill or for oat flour which could be added to cereals, etc.

[lscfa]

Forget about it. Nasdaq listing is another $1 million Cdn per year expense.... https://www.newswire.ca/news-releases/quarterhill-announces-u-s-delisting-and-deregistration-835954224.html

[prophetoffactz]

Avalyn raised C$80 million going into its inhaled Phase I fibrosis clinical trial. Dr. Ask and Dr. Kolb of McMaster both worked with that company and have both expressed their excitement about CZO's program with Dr. Kolb saying CZO could profoundly alter the landscape if results in mice are replicated in humans. COVID fibrosis wasn't around when Avalyn raised the C$80 million and CZO's